Glycogen storage disease type III

Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 19, 2022
Health, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, OTC, Gene editing, Infection, Hepatitis B virus, Severe acute respiratory syndrome coronavirus 2, Webcast, RNA, Liver, Patent, RNA transfection, Wright Investors' Service Holdings, Inc., III, COVID-19, Messenger RNA, Conference, Annual, ARCT, DNA, Glycogen storage disease type III, Therapy, Vaccine, Cystic fibrosis

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
  • A webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar .
  • Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
  • Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Pharmaceutical, General Health, Health, Infectious Diseases, Genetics, Clinical Trials, Other Health, Berkeley, Therapy, III, Global Vaccines, ARCT, Infection, Chemical engineering, University, Severe acute respiratory syndrome coronavirus 2, OTC, DNA, Gene editing, Liver, Glycogen storage disease type III, Policy, Messenger RNA, Hepatitis B virus, COVID-19, RNA transfection, Vaccine, Multimedia, Technology transfer, Merck & Co., Delaware Department of Transportation, RNA, Kirkbi AG v Ritvik Holdings Inc, Patent, Cystic fibrosis, Pharmaceutical industry, Arcturus, Merck

View the full release here: https://www.businesswire.com/news/home/20221213005428/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221213005428/en/
    We are very pleased to welcome Dr. John Markels to the Arcturus Board, said Joseph Payne, President & CEO of Arcturus.
  • John is an accomplished industry leader with exceptional vaccine and manufacturing expertise gained from a prolific career with Merck.
  • I look forward to working closely with the team to support the manufacturing and delivery of next generation mRNA medicines and vaccines globally, said John Markels, Ph.D., Director at Arcturus.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Therapeutics to Present at the Following Investor Conferences in November

Retrieved on: 
Monday, November 7, 2022
COVID-19, Infectious Diseases, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Infection, Hepatitis B virus, ARCT, Liver, III, Company, Vaccine, RNA transfection, Gene editing, OTC, RNA, Cystic fibrosis, Messenger RNA, Wright Investors' Service Holdings, Inc., COVID-19, Glycogen storage disease type III, Nasdaq, DNA, Patent, Therapy, Severe acute respiratory syndrome coronavirus 2

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, self-amplifying RNA, antisense RNA, circular RNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Nephrology, Arcturus Therapeutics, RNA transfection, RNA, Annual report, DNA, Risk, CEO, Influenza, MicroRNA, COVID, Liver, CSL Behring, Partnership, SEC, ARCT, Hart–Scott–Rodino Antitrust Improvements Act, Hepatitis B virus, Research, Glycogen storage disease type III, Haemophilia, LLC, Intention, Nasdaq, COVID-19, Dialysis, Infection, III, CSL, R, Cystic fibrosis, Associated Press v. Meltwater U.S. Holdings, Inc., Patent, Technology, Immunodeficiency, Vaccine, LNP, Private Securities Litigation Reform Act, Company, CSL Limited, Therapy, Gene editing, ASX, Patient, Iron deficiency, OTC, Severe acute respiratory syndrome coronavirus 2, Messenger RNA, Biotechnology, Pharmaceutical industry, Arcturus

The collaboration combines CSL Seqirus established global vaccine commercial and manufacturing infrastructure with Arcturus manufacturing expertise and innovative STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies.

Key Points: 
  • The collaboration combines CSL Seqirus established global vaccine commercial and manufacturing infrastructure with Arcturus manufacturing expertise and innovative STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies.
  • Arcturus will bring its mRNA design and modification expertise, LUNAR lipid nanoparticle (LNP) technology and manufacturing know-how, which has enabled the Companys low dose, lyophilized and durable self-amplifying mRNA vaccines against COVID-19.
  • We are excited to embark on this collaboration with CSL Seqirus, a respected world leader in the development, manufacture and commercialization of vaccines, said Joseph Payne, President and CEO of Arcturus Therapeutics.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

Retrieved on: 
Wednesday, October 26, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, LinkedIn, MicroRNA, RNA transfection, Therapy, Cystic Fibrosis Foundation, Vaccine, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, Glycogen storage disease type III, Gene editing, Janssen Pharmaceuticals, RNA, Twitter, Diversified Specialty Institute Holdings, Inc., Nasdaq, Cystic fibrosis, Hepatitis B virus, III, ARCT, Patent, OTC, DNA, Messenger RNA, COVID-19, Baking

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • Arcturus commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation.
  • In addition, please connect with us on Twitter and LinkedIn .

Arcturus Therapeutics to Attend the Following Investor Conferences

Retrieved on: 
Tuesday, September 27, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, Janssen Pharmaceuticals, COVID-19, Twitter, Infection, Gene editing, RNA transfection, Severe acute respiratory syndrome coronavirus 2, MicroRNA, LinkedIn, Company, Cystic Fibrosis Foundation, Johnson & Johnson, OTC, III, Hepatitis B virus, Vaccine, Nasdaq, Liver, Wright Investors' Service Holdings, Inc., Messenger RNA, RNA, DNA, Cystic fibrosis, Patent, Glycogen storage disease type III, ARCT

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • Arcturus commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation.

Arcturus Therapeutics to Attend the Following Investor Conferences

Retrieved on: 
Thursday, September 1, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, COVID-19, RNA, OTC, Janssen Pharmaceuticals, Hepatitis B virus, Liver, Gene editing, Vaccine, Wright Investors' Service Holdings, Inc., Cystic Fibrosis Foundation, ARCT, MicroRNA, LinkedIn, DNA, Infection, Cystic fibrosis, Patent, Messenger RNA, Severe acute respiratory syndrome coronavirus 2, Nasdaq, Company, Therapy, Twitter, III, Johnson & Johnson, RNA transfection, Glycogen storage disease type III

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • Arcturus commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation.

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Retrieved on: 
Wednesday, August 31, 2022
COVID-19, Infectious Diseases, FDA, Clinical Trials, Public Policy, Government, Biotechnology, Pharmaceutical, Health, Public Policy, Other Policy Issues, COVID-19, Contract, CEO, Technology, RNA, OTC, Janssen Pharmaceuticals, Liver, Government, Therapy, Arcturus Therapeutics, Gene editing, Vaccine, Kirkbi AG v Ritvik Holdings Inc, Cystic Fibrosis Foundation, Disease, Risk, ARCT, MicroRNA, BARDA, LinkedIn, Department, DNA, SEC, Biomedical Advanced Research and Development Authority, Infection, Cystic fibrosis, Patent, National Strategy for Trusted Identities in Cyberspace, Hepatitis B, Severe acute respiratory syndrome coronavirus 2, Intention, Nasdaq, Assistant, Twitter, III, Johnson & Johnson, Annual report, RNA transfection, Private Securities Litigation Reform Act, Development, Glycogen storage disease type III, Arcturus

The award provides $63.2 million over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 clinical studies.

Key Points: 
  • The award provides $63.2 million over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 clinical studies.
  • We are very pleased to have won this substantial award from the BARDA and look forward to working with the U.S. government to support the development of our proprietary self-amplifying mRNA vaccine technology for rapid pandemic influenza response.
  • These are qualities that are essential to a rapid response against pandemic influenza and are consistent with strategic objectives of the U.S. governments National Strategy for Pandemic Influenza.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Retrieved on: 
Thursday, August 18, 2022
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Janssen Pharmaceuticals, Liver, III, Multimedia, Johnson & Johnson, Cystic Fibrosis Foundation, CEO, Diagnosis, Messenger RNA, Private Securities Litigation Reform Act, ARCT, SEC, Clinical trial, Glycogen storage disease type III, Infection, MNT, Patent, Annual report, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Gene editing, DNA, Therapy, COVID-19, Twitter, Cystic fibrosis, Vaccine, OTC, RNA, C.I, Safety, Risk, Intention, Vaccination, Arcturus Therapeutics, MicroRNA, Hepatitis B virus, Nasdaq, Severe acute respiratory syndrome coronavirus 2, LinkedIn, RNA transfection, Omicron, Arcturus

In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).

Key Points: 
  • In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).
  • Neutralizing antibody responses against Omicron variants BA.1, BA.2, and BA.5 were measured at the Moore Lab in South Africa.
  • These data show sustained neutralizing responses to antigenically distinct variants of concern, including Omicron BA.5, for at least six months after vaccination.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

 Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

Retrieved on: 
Monday, August 1, 2022
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, DNA, Severe acute respiratory syndrome coronavirus 2, III, Twitter, Johnson & Johnson, Diversified Specialty Institute Holdings, Inc., Janssen Pharmaceuticals, ARCT, Patent, COVID-19, RNA transfection, Hepatitis B, Cystic Fibrosis Foundation, LinkedIn, Nasdaq, Therapy, Glycogen storage disease type III, Gene editing, MicroRNA, Cystic fibrosis, OTC, RNA, Vaccine, Baking

Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Key Points: 
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • Arcturus commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation.
  • addition, please connect with us on Twitter and LinkedIn.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005045/en/